Literature DB >> 9100477

Significance of postoperative serum level of carcinoembryonic antigen (CEA) and actual half life of CEA in colorectal cancer patients.

J S Choi1, J S Min.   

Abstract

The postoperative levels of carcinoembryonic antigen (CEA) and the actual half life (T1/2) of CEA were evaluated to ascertain their potency in predicting the recurrence of colorectal cancer after curative surgery in patients who had an abnormally high level of preoperative carcinoembryonic antigen (CEA, > or = 5 ng/ml). Ninety-four patients who underwent curative surgery were enrolled and 24 patients (25.5%) had recurrence during the follow-up period (median: 30 months, range: 2-69 months). T1/2 of CEA for all patients ranged from 1.2 days to 88.1 days, with a median of 4.4 days. T1/2 of CEA (mean +/- standard deviation) was 11.7 +/- 17.9 days in recurrent patients, whereas it was 6.2 +/- 4.9 days in patients without recurrence (p = 0.0224). The patients' age, gender, size of the tumor, location of the tumor, pre-, and postoperative CEA level, pathologic type of the tumor and Dukes stage had no significance in recurrence. The 1-year, 2-year, and 5-year disease-free survival rates were 95.1%, 81.1%, and 73.8% in patients with postoperative CEA levels less than 5 ng/ml (n = 62), respectively, and 71.4%, 64.8%, and 64.8% in patients with postoperative CEA levels higher than or equal to 5 ng/ml (n = 32), respectively (p = 0.04). Patients were divided into Group S (T1/2 of CEA < 4.4 days, n = 43) and Group L (T1/2 of CEA > or = 4.4 days, n = 51). The 1-year, 2-year, and 5-year disease-free survival rates were 95.3%, 85.1%, and 77.7% in Group S, respectively, and 80%, 67.5%, and 64.1% in Group L, respectively (p = 0.0261). In conclusion, the disease-free survival of colorectal cancer patients was prolonged in patients who had a short T1/2 of CEA or a low level of postoperative CEA. In high-risk colorectal cancer patients with an abnormally high level of preoperative CEA, recurrence may be predicted by checking an early postoperative CEA level and/or by a simple calculation of the actual half life of CEA.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9100477     DOI: 10.3349/ymj.1997.38.1.1

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  10 in total

1.  Impact of the post/preoperative serum CEA ratio on the survival of patients with rectal cancer.

Authors:  Tsukasa Hotta; Katsunari Takifuji; Shozo Yokoyama; Kenji Matsuda; Yoshimasa Oku; Toru Nasu; Junji Ieda; Naoyuki Yamamoto; Hiromitsu Iwamoto; Yoh Takei; Yuki Mizumoto; Hiroki Yamaue
Journal:  Surg Today       Date:  2014-02-07       Impact factor: 2.549

2.  Clinical significance of serum anti-p53 antibody expression following curative surgery for colorectal cancer.

Authors:  Kensuke Kumamoto; Hideyuki Ishida; Koki Kuwabara; Kunihiko Amano; Noriyasu Chika; Norimichi Okada; Tomonori Ohsawa; Youichi Kumagai; Keiichiro Ishibashi
Journal:  Mol Clin Oncol       Date:  2017-08-08

3.  Early postoperative CEA level is a better prognostic indicator than is preoperative CEA level in predicting prognosis of patients with curable colorectal cancer.

Authors:  Jen-Kou Lin; Chun-Chi Lin; Shung-Haur Yang; Huann-Sheng Wang; Jeng-Kai Jiang; Yuan-Tzu Lan; Tzu-Chen Lin; Anna Fen-Yau Li; Wei-Shone Chen; Shih-Ching Chang
Journal:  Int J Colorectal Dis       Date:  2011-05-03       Impact factor: 2.571

4.  Prognostic value of postoperative CEA clearance in rectal cancer patients with high preoperative CEA levels.

Authors:  Jeong Yeon Kim; Nam Kyu Kim; Seung Kook Sohn; Yong Wan Kim; Kim Jin Soo Kim; Hyuk Hur; Byung Soh Min; Chang Hwan Cho
Journal:  Ann Surg Oncol       Date:  2009-08-06       Impact factor: 5.344

5.  Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome.

Authors:  Tsuyoshi Konishi; Yoshifumi Shimada; Meier Hsu; Lauren Tufts; Rosa Jimenez-Rodriguez; Andrea Cercek; Rona Yaeger; Leonard Saltz; J Joshua Smith; Garrett M Nash; José G Guillem; Philip B Paty; Julio Garcia-Aguilar; Mithat Gonen; Martin R Weiser
Journal:  JAMA Oncol       Date:  2018-03-01       Impact factor: 31.777

Review 6.  Blood CEA levels for detecting recurrent colorectal cancer.

Authors:  Brian D Nicholson; Bethany Shinkins; Indika Pathiraja; Nia W Roberts; Tim J James; Susan Mallett; Rafael Perera; John N Primrose; David Mant
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10

7.  New insights into the role of age and carcinoembryonic antigen in the prognosis of colorectal cancer.

Authors:  P G Gobbi; F Valentino; E Berardi; C Tronconi; S Brugnatelli; O Luinetti; R Moratti; G R Corazza
Journal:  Br J Cancer       Date:  2007-11-20       Impact factor: 7.640

8.  CEA clearance pattern as a predictor of tumor response to neoadjuvant treatment in rectal cancer: a post-hoc analysis of FOWARC trial.

Authors:  Huabin Hu; Jin Huang; Ping Lan; Lei Wang; Meijin Huang; Jianping Wang; Yanhong Deng
Journal:  BMC Cancer       Date:  2018-11-20       Impact factor: 4.430

9.  The prognostic value of the postoperative serum CEA levels/preoperative serum CEA levels ratio in colorectal cancer patients with high preoperative serum CEA levels.

Authors:  Hai-Lun Xie; Yi-Zhen Gong; Jia-An Kuang; Feng Gao; Shuang-Yi Tang; Jia-Liang Gan
Journal:  Cancer Manag Res       Date:  2019-08-07       Impact factor: 3.989

10.  Postoperative serum carcinoembryonic antigen levels cannot predict survival in colorectal cancer patients with type II diabetes.

Authors:  Chih-Sheng Huang; Chin-Yau Chen; Li-Kuo Huang; Wei-Shu Wang; Shung-Haur Yang
Journal:  J Chin Med Assoc       Date:  2020-10       Impact factor: 3.396

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.